

OBJAVLJENI RADOVI ISTRAŽIVAČA IORSa u 2021. godini (izvor: Indeksna baza SCOPUS)

- (1) Stevanović N, Mazzeo PP, Bacchi A, Matić IZ, Đordić Crnogorac M, Stanojković T, et al. Synthesis, characterization, antimicrobial and cytotoxic activity and DNA-binding properties of d-metal complexes with hydrazones of Girard's T and P reagents. *J Biol Inorg Chem* 2021;26(8):863-880. IF 3.358
- (2) Vuletić A, Mirjačić Martinović K, Tišma Miletić N, Zoidakis J, Castellvi-Bel S, Čavić M. Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. *Front Cell Dev Biol* 2021;9. IF 6.684
- (3) Prvanović M, Nedeljković M, Tanić N, Tomić T, Terzić T, Milovanović Z, et al. Role of pten, pi3k, and mtor in triple-negative breast cancer. *Life* 2021;11(11).
IF 3.817
- (4) Simic M, Petkovic M, Jovanovic P, Jovanovic M, Tasic G, Besu I, et al. Fragment-type 4-azolylcoumarin derivatives with anticancer properties. *Arch Pharm* 2021;354(11).
IF 3.751
- (5) Stojanovic-Rundic S, Marinkovic M, Cacic M, Karapandzic VP, Gavrilovic D, Jankovic R, et al. The role of haematological parameters in predicting the response to radical chemoradiotherapy in patients with anal squamous cell cancer. *Radiol Oncol* 2021;55(4):449-458. IF 2.991
- (6) Nikolic N, Radosavljevic D, Gavrilovic D, Nikolic V, Stanic N, Spasic J, et al. Prognostic factors for post-recurrence survival in stage ii and iii colorectal carcinoma patients. *Medicina* 2021;57(10).
IF 2.430
- (7) Stanić D, Grujičić D, Pekmezović T, Bokun J, Popović-Vuković M, Janić D, et al. Clinical profile, treatment and outcome of pediatric brain tumors in Serbia in a 10-year period: A national referral institution experience. *PLoS ONE* 2021;16(10 October).
IF 3.240
- (8) Petronijević J, Joksimović N, Milović E, Crnogorac MĐ, Petrović N, Stanojković T, et al. Antitumor activity, DNA and BSA interactions of novel copper(II) complexes with 3,4-dihydro-2(1H)-quinoxalinones. *Chem -Biol Interact* 2021;348.
IF 5.194
- (9) Ušjak LJ, Milutinović VM, Đordić Crnogorac MJ, Stanojković TP, Niketić MS, Kukić-Marković JM, et al. Barks of Three Wild Pyrus Taxa: Phenolic Constituents, Antioxidant Activity, and in Vitro and in Silico Investigations of α -Amylase and α -Glucosidase Inhibition. *Chem Biodiversity* 2021;18(10).
IF 2.408
- (10) Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, et al. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. *Breast* 2021;59:327-338. IF 4.380
- (11) Dómine Gómez M, Csószi T, Jaal J, Kudaba I, Nikolov K, Radosavljevic D, et al. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer. *Int J Cancer* 2021;149(7):1463-1472.
IF 7.396

- (12) Todorović-Raković N, Whitfield JR. Between immunomodulation and immunotolerance: The role of IFN γ in SARS-CoV-2 disease. *Cytokine* 2021;146. IF 3.861
- (13) Fabian ID, Stacey AW, Foster A, Kivelä TT, Munier FL, Keren-Froim N, et al. Travel burden and clinical presentation of retinoblastoma: Analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries. *Br J Ophthalmol* 2021;105(10):1435-1443. IF 4.638
- (14) Stepanovic A, Arsenijevic T, Stankovic V, Vujanac V, Lazovic A, Raonic-Stevanovic T, et al. Clinical analysis of COVID-19 positive cancer inpatients in National Cancer Center in Serbia. *J Infect Dev Ctries* 2021;15(9):1286-1292. IF 0.968
- (15) Todorović-Raković N, Milovanović J, Greenman J, Radulovic M. The significance of HOXB7 and IL17RB serum levels in prognosis of hormonally dependent breast cancer: A pilot study. *Adv Med Sci* 2021;66(2):359-365. IF 3.287
- (16) Adzic NM, Obradovic KV, Urban VP, Mijaljevic MB, Radmanovic BJ, Milosevic ZC. Computed tomography features of pulmonary metastases from angiosarcoma: Lessons learned from one case study. *Radiol Case Rep* 2021;16(9):2646-2650. IF- MEDLINE
- (17) Crnogorac MĐ, Matić IZ, Damjanović A, Janković N, Krivokuća A, Stanojković T. 3D HeLa spheroids as a model for investigating the anticancer activity of Biginelli-hybrids. *Chem -Biol Interact* 2021;345. IF 5.194
- (18) Djurić GJ, Rajković N, Milošević N, Septa JP, Borić I, Dučić S, et al. Computational analysis of MRIs predicts osteosarcoma chemoresponsiveness. *Biomarkers Med* 2021;15(12):929-940. IF 2.851
- (19) Matić IZ, Grujić M, Kolundžija B, Damjanović A, Tomašević Z, Đorđić Crnogorac M, et al. White blood cell subsets in HER2-positive breast cancer patients treated with trastuzumab in relation to clinical outcome. *Pathol Res Pract* 2021;224. IF 3.250
- (20) Stojanović-Rundić S, Plešinac-Karapandžić V, Dedović-Stojaković J, Mijalković N, Škrelja V, Miletić N, et al. Can multidisciplinary approach win the battle against metastatic rectal cancer? *Srp Arh Celok Lek* 2021;149(7-8):494-498. IF 0.207
- (21) O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. *Eur J Cancer* 2021;152:223-232. IF 9.162
- (22) Matkovic S, Dotlic J, Gazibara T, Maric G, Nikolic V, Maksimovic N. Functional assessment of cancer therapy questionnaire for melanoma in the Serbian population: A factor analytic approach. *PLoS ONE* 2021;16(6 June). IF 3.240
- (23) Todorović-Raković N, Milovanović J, Durosaro SO, Radulovic M. The prognostic value of cyclin D1 in breast cancer patients treated with hormonal therapy: A pilot study. *Pathol Res Pract* 2021;222. IF 3.250
- (24) Matić IZ, Ergün S, Đorđić Crnogorac M, Misir S, Aliyazıcıoğlu Y, Damjanović A, et al. Cytotoxic activities of Hypericum perforatum L. extracts against 2D and 3D cancer cell models. *Cytotechnology* 2021;73(3):373-389. IF 2.058

(25) Nešić A, Čavić M, Popović M, Gavrović-Jankulović M. A new approach for activation of the kiwifruit cysteine protease for usage in in-vitro testing. *Mol Biol Rep* 2021;48(5):4065-4072.

IF 2.316

(26) Nedeljković M, Tanić N, Prvanović M, Milovanović Z, Tanić N. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer. *Breast Cancer* 2021;28(3):727-736.

IF 4.239

(27) Andrijic M, Tepavcevic DK, Nikitovic M, Miletic N, Pekmezovic T. Prevalence of burnout among healthcare professionals at the Serbian National Cancer Center. *Int Arch Occup Environ Health* 2021;94(4):669-677.

IF 3.015

(28) Santric V, Dragicevic D, Matic M, Djokic M, Pljesa-Ercegovac M, Radic T, et al. Polymorphisms in Genes Encoding Glutathione Transferase Pi and Glutathione Transferase Omega Influence Prostate Cancer Risk and Prognosis. *Front Mol Biosci* 2021;8.

IF 5.246

(29) Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, et al. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. *ESMO Open* 2021;6(2).

IF 6.540

(30) Ferrari A, Stark D, Peccatori FA, Fern L, Laurence V, Gaspar N, et al. Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE). *ESMO Open* 2021;6(2).

IF 6.540

(31) Bozovic-Spasojevic I, Balsat M, Blondeel A, Castleton A, De Munter J, Gamble AS, et al. A European Network for Teenagers and Young Adults with Cancer. *J Adolesc Young Adult Oncol* 2021;10(2):117-119.

IF 2.223

(32) Jovanović M, Tenji D, Nikolić B, Srdić-Rajić T, Svirčev E, Mitić-ćulafić D. In vitro study of two edible polygonoideae plants: Phenolic profile, cytotoxicity, and modulation of keap1-nrf2 gene expression. *Foods* 2021;10(4).

IF 4.350

(33) Moreno E, Cavic M, Canela EI. Functional fine-tuning of metabolic pathways by the endocannabinoid system—implications for health and disease. *Int J Mol Sci* 2021;22(7).

IF 5.924

(34) Jauković V, Krajišnik D, Daković A, Damjanović A, Krstić J, Stojanović J, et al. Influence of selective acid-etching on functionality of halloysite-chitosan nanocontainers for sustained drug release. *Mater Sci Eng C* 2021;123.

IF 7.328

(35) Adkins DR, Lin J-, Sacco A, Ley J, Oppelt P, Vanchenko V, et al. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. *Oral Oncol* 2021;115.

IF 5.337

- (36) Petrović BS, Faj DZ, Marković MB, Tot AA, Marjanović MS, Kasabašić MD, et al. Assessment of computed tomography simulators used in radiotherapy treatment planning in serbia, croatia, and bosnia and herzegovina. *Nuc Tech Rad Prot* 2021;36(1):97-106. IF 1.242
- (37) Radenkovic S, Konjevic G, Nikitovic M, Stojanovic-Rundic S, Plesinac-Karapandzic V, Milovic-Kovacevic M, et al. Evaluation of Cyclin D1 expression by western blotting methods and immunohistochemistry in breast cancer patients. *J B U ON* 2021;26(2):475-482. IF 2.533
- (38) Uzelac B, Krivokuća A, Susnjarić S, Milovanović Z, Supić G. Histone Deacetylase 7 Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients. *Genet Test Mol Bioma* 2021;25(3):227-235. IF 1.795
- (39) Huijskens SC, Kroon PS, Gaze MN, Gandola L, Bolle S, Supiot S, et al. Radical radiotherapy for paediatric solid tumour metastases: An overview of current European protocols and outcomes of a SIOPE multicenter survey. *Eur J Cancer* 2021;145:121-131. IF 9.162
- (40) Tadić JD, Lađarević JM, Vitnik ŽJ, Vitnik VD, Stanojković TP, Matić IZ, et al. Novel azo pyridone dyes based on dihydropyrimidinone skeleton: Synthesis, DFT study and anticancer activity. *Dyes Pigm* 2021;187. IF 4.889
- (41) Peck B, Bland P, Mavrommatis I, Muirhead G, Cottom H, Wai PT, et al. 3D functional genomics screens identify CREBBP as a targetable driver in aggressive triple-negative breast cancer. *Cancer Res* 2021;81(4):847-859. IF 12.701
- (42) Jotic AD, Milovanovic JP, Trivic AS, Folic MM, Krejovic-Trivic SB, Radin ZZ, et al. Predictors of Complications Occurrence Associated With Emergency Surgical Tracheotomy. *Otolaryngol Head Neck Surg* 2021;164(2):346-352. IF 3.497
- (43) Vukajlović JT, Kosanić M, Ranković B, Stanojković T, Marković A, Grujičić D, et al. Evaluation of biological activities of acetone extract of the mushroom leccinum scabrum. *Farmacia* 2021;69(5):974-979. IF 1.433
- (44) Veličković I, Žižak Ž, Simin N, Bekvalac K, Ivanov M, Soković M, et al. Phenolic profile and biological potential of wild blackberry (*Rubus discolor*) fruits. *Bot Serbica* 2021;45(2):215-222. IF 0.468
- (45) Kerpel-Fronius A, Tammemägi M, Cavic M, Henschke C, Jiang L, Kazerooni E, et al. Screening for Lung Cancer in Individuals Who Never Smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report. *J Thorac Oncol* 2021. IF 15.609
- (46) Krivokuća A, Mihajlović M, Susnjarić S, Spasojević IB, Minic I, Popović L, et al. Mutational profile of hereditary breast and ovarian cancer – Establishing genetic testing guidelines in a developing country. *Curr Probl Cancer* 2021. IF 3.187
- (47) ČOBELJIĆ BR, ŽIVKOVIĆ MB, MATIĆ IZ, NOVAKOVIĆ IT, SLADIĆ DM, ANDELKOVIĆ KK, et al. Synthesis, characterization and biological activity of pt(ii) complexes with steroid thiosemicarbazones. *J Serb Chem Soc* 2021;86(5):459-468. IF 1.823

(48) Todorović-Raković N. Chromogenic in situ hybridization (CISH) as a method for detection of C-Myc amplification in formalin-fixed paraffin-embedded tumor tissue: An update. *Methods Mol Biol* 2021;2318:313-320.
MEDLINE - book chapter

(49) Veličkovi I, Žižak Ž, Rajčevi N, Ivanov M, Soković M, Marin PD, et al. *Prunus spinosa L.* leaf extracts: polyphenol profile and bioactivities. *Not Bot Horti Agrobot Cluj-Napoca* 2021;49(1):1-12.

IF 1.444

(50) Stanić J, Stanković V, Nikitović M. Modern radiotherapy in the treatment of localized prostate cancer. *Srp Arh Celok Lek* 2021;149(1-2):117-121.

IF 0.207

(51) Grahovac J, Pavlović M, Ostojić M. A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells. *Methods Mol Biol* 2021;2265:73-80.

MEDLINE - book chapter

(52) Jokic V, Savic-Vujovic K, Spasic J, Stanic N, Marinkovic M, Radosavljevic D, et al. Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. *Expert Rev Anticancer Ther* 2021;21(6):673-679.

IF 4.512

(53) Petrović N, Nakashidze I, Nedeljković M. Correction to: Breast Cancer Response to Therapy: Can microRNAs Lead the Way? (*Journal of Mammary Gland Biology and Neoplasia*, (2021), 10.1007/s10911-021-09478-3). *J Mammary Gland Biol Neoplasia* 2021.
correction to...

(54) Petrović N, Nakashidze I, Nedeljković M. Breast Cancer Response to Therapy: Can microRNAs Lead the Way? *J Mammary Gland Biol Neoplasia* 2021.

IF 2.673

(55) Todorović-Raković N. The role of cytokines in the evolution of cancer: IFN- γ paradigm. *Cytokine* 2021.

IF 3.861

(56) Cavic M, Krivokuća A, Pavlović M, Boljević I, Rakobradović J, Mihajlović M, et al. EGFR mutation testing from liquid biopsy of non-small cell lung cancer at the Institute for Oncology and Radiology of Serbia. *J B U ON* 2021;25(6):2635-2648.

IF 2.533

(57) Cavic M, Krivokuća A, Boljević I, Spasic J, Mihajlović M, Pavlović M, et al. Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals. *Expert Rev Mol Diagn* 2021;21(1):101-107.

IF 5.225

(58) Sofrenić I, Andelković B, Todorović N, Stanojković T, Vujišić L, Novaković M, et al. Cytotoxic triterpenoids and triterpene sugar esters from the medicinal mushroom *Fomitopsis betulina*. *Phytochemistry* 2021;181.

IF 4.072

(59) Hart LL, Ferrarotto R, Andric ZG, Beck JT, Subramanian J, Radosavljevic DZ, et al. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. *Adv Ther* 2021;38(1):350-365.

IF 3.847

U 2021. godini objavljeno je 59 radova .

Projekti:

Od 59 radova, 37 radova je sponzorisalo **Ministarstvo prosvete nauke i tehnoloskog razvoja,**
AstraZeneca 6, Pfizer 5, Science Fund of the Republic of Serbia 6, Bristol-Meyers Squibb 4, Merck 4, i drugi..

Vrste radova:

50	naučnih radova
2	revijskih radova
2	poglavlja u knjigama
1	erratum (Ispravka)
1	editorial – uvodni rad

Kategorizacija:

Samo ovih 59 radova iz 2021 citirano je **71** puta

H index objavljenih radova u 2021. - **4**

Prema urađenoj kategorizaciji, kumulativni IF radova objavljenih u 2021. godini iznosi **227.386**

Autori sa najviše objavljenih autora u 2021. godini:

Čavić Milena

Stanojković Tatjana P

Matić Ivana Z

Nikitović Marina

Todorović Raković Nataša

Damjanović Ana

Krivokuća Ana

Nedeljković M

Petrović Nina

Radosavljević Davorin